Eli Lilly CEO Delivers Stark Message on What Comes Next

Eli Lilly Might Be the Next Stock I Buy

The company has a history of developing treatments that have achieved widespread adoption.

Prediction: Eli Lilly's Next Growth Wave Could Surprise Investors

Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that tension shapes whether shares have another 20% to climb or stall near today's levels.

Eli Lilly CEO delivers stark message on what comes next

In 1977, Ken Langone received Eli Lilly shares for a medical device company he had acquired for $1.5 million. He has never sold a single share. I covered his story on Sept. 25 — the two crises he bought through, the golf game where his trader kept buying while he played, the conviction that now…